We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





COVID-19 Molecular Diagnostics Fueling Growth of Global Infectious Disease In-Vitro Diagnostics Market

By LabMedica International staff writers
Posted on 30 Apr 2021
Print article
Illustration
Illustration
The global infectious disease in-vitro diagnostics market is projected to record promising growth over the 2020-2030 period on back of the rising prevalence of infectious diseases around the world, particularly COVID-19.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.

Infectious disease in-vitro diagnostic tests perform the function of detecting and identifying the specific infectious agent to establish its origin and enable healthcare professionals to provide the ideal treatment to a patient. These tests can also help in overcoming potential epidemics. This is acting as a vital growth generator for the infectious disease in-vitro diagnostics market. The increasing incidences of infectious diseases and the growing need to tackle them at an early stage have led to tremendous advancements in terms of diagnostics. Infectious disease in-vitro diagnostics is one of them. Thus, this will bring good growth opportunities for the infectious disease in-vitro diagnostics market.

The overwhelming use of infectious disease in-vitro diagnostics in point-of-care testing, central laboratories and others will create immense growth prospects for the market. The growing influence of infectious disease in-vitro diagnostics in detecting a variety of infections such as respiratory viruses, Chlamydia, HPV, Gonorrhea, Clostridium Difficile, MRSA, Streptococcus, Hepatitis B, HIV, Hepatitis C, COVID-19, and others will serve as a vital growth-generator.

The COVID-19 pandemic has wreaked havoc across the globe due to the rising transmission rates and fatality rates. The most efficient way to decrease the mortality rate and prevent infecting others is an intense focus on testing. For COVID-19 testing, RT-PCR (real-time reverse transcription-polymerase chain reaction) is regarded as a gold standard. This testing method is the clinical gold standard for the etiological diagnosis of COVID-19 in which viral DNA is directly detected. RT-PCR tests are being considered as the best option for COVID-19 testing around the world. The growing popularity of these testing methods will create huge growth prospects for the infectious disease in-vitro diagnostics market.

Manufacturers in the infectious disease in-vitro diagnostics market are developing kits that are easier for home use. These kits are designed for home-testing and treatments. Self-testing kits are useful for early diagnosis and consistent patient monitoring. They are also important for curbing costs. Hence, the rising demand for self-testing kits is directly proportional to the growth of the infectious disease in-vitro diagnostics market.

Geographically, North America will continue to dominate the global infectious disease in-vitro diagnostics market with the largest share between 2020 and 2030 on the back of the rising COVID-19 infections across the region. However, the Asia Pacific infectious disease in-vitro diagnostics market is expected to record the fastest growth during this period.

Related Links:
TMR Research

Gold Supplier
SARS-CoV-2 Rapid Test
Vivalytic SARS-CoV-2 Rapid 39 Minute Test
New
Refrigerated Centrifuge
Centrisart G-26C
New
Silver Supplier
SARS-CoV-2 qRT-PCR IVD Reagent Kit
SARS-CoV-2 qRT-PCR Dx Kit (CE-IVD)
New
Gold Supplier
TRANSPORT MEDIUM
TRANSPORT MEDIUM-2

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.